During the coronavirus disease 2019 (Covid-19) pandemic, the emergence of the BA.1, BA.2, and BA.3 sublineages of the B.1.1.529 (omicron) variant of severe acute respiratory syndrome coronavirus 2 ...

The neutralizing activity of all serum samples was tested against the B.1.429 variant and a variant of concern that first emerged in South Africa (B.1.351, also called 20H/501Y.V2). We compared this ...

A recent paper, currently available on bioRxiv* preprint server, reveals the potential for a common class of public antibodies to develop broad cross-neutralization against the severe acute ...

In the absence of effective treatments for COVID-19, many countries have approved the therapeutic use of blood plasma from recovering patients because it contains antibodies against the coronavirus.